Infectious Disease Section, Virginia Tech Carilion School of Medicine, Roanoke, VA, USA.
Infectious Disease Section, Virginia Tech Carilion School of Medicine, Roanoke, VA, USA.
Int J Antimicrob Agents. 2023 Apr;61(4):106749. doi: 10.1016/j.ijantimicag.2023.106749. Epub 2023 Feb 8.
Dalbavancin is a parenteral lipoglycopeptide antibiotic derived from teicoplanin, an analogue of vancomycin. It is mainly used for skin and soft tissue infections. The sustained half-life of approximately 14 days makes dalbavancin a novel option for potential use as sequential treatment in infections such as infective endocarditis, which require prolonged antibiotic courses. However, only a few studies have been reported in the literature, and the use of dalbavancin remains limited. This article is a review of the currently available literature using dalbavancin for the treatment of infective endocarditis due to Gram-positive organisms. Almost all patients received dalbavancin as sequential therapy following standard-of-care antibiotics. The overall clinical efficacy of dalbavancin was approximately 90%, and it appeared to be well tolerated.
达巴万星是一种从万古霉素类似物替考拉宁衍生而来的注射用糖肽类抗生素。它主要用于治疗皮肤和软组织感染。达巴万星约 14 天的半衰期使它成为治疗感染性心内膜炎等需要长期使用抗生素的疾病的潜在序贯治疗的新选择。然而，目前文献中仅报道了少数研究，且达巴万星的使用仍然有限。本文综述了目前使用达巴万星治疗革兰阳性菌引起的感染性心内膜炎的相关文献。几乎所有患者在接受标准治疗抗生素后，均使用达巴万星进行序贯治疗。达巴万星的总体临床疗效约为 90%，且耐受性良好。
